Urothelial Cancer Drugs Market 2030: A Focus on Immunotherapy
Global Urothelial Cancer Drugs Market Overview The global urothelial cancer drugs market was valued at USD 3.24 billion in 2023 and is projected to reach USD 6.78 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.1% from 2024 to 2030. This robust growth is primarily driven by the increasing prevalence of urothelial cancer, especially bladder cancer. Advancements in cancer treatment, including the emergence of targeted therapies and immunotherapies, have broadened treatment options, enabling more personalized and effective care for patients. Additionally, pharmaceutical companies’ rising investments in research and development (R&D) are fueling market expansion. The growth of the geriatric population, who are more vulnerable to urothelial cancer, also plays a significant role. Moreover, increased awareness and early diagnosis of bladder-related diseases are encouraging more patients to pursue treatment, further propelling market growth. There has been a...